UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


Washington, D.C.  20549 

 

FORM 8-K



CURRENT REPORT 

 Pursuant to Section 13 or 15(d)
     

  of the Securities Exchange Act of 1934




Date of Report (Date of earliest event reported):   December 3, 2007

Protalix BioTherapeutics, Inc.


(Exact name of registrant as specified in its charter)


Florida

(State or other jurisdiction of incorporation)


  
     
     
     
  
  
    000-27836

      (Commission File Number) 
     
    65-0643773

      (IRS Employer Identification No.)
  
  
     
     
     
  
  
    2 Snunit Street
        

      Science Park

POB 455


Carmiel, Israel


      (Address of principal executive offices) 
     
    

      

      

      20100

    (Zip Code)
  




Registrant’s telephone number, including area code: +972-4-988-9488

(Former Name or Former Address, if Changed Since Last Report)


 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):




    o
     
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



     


    o
     
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



     


    o
     
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



     


    o
     
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



 
 
 
 








Item 8.01. Other Events
On December 3, 2007, Protalix BioTherapeutics, Inc. (the “Company”), issued a press release noting that prGCD, the Company’s proprietary recombinant form of Glucocerebrosidase (GCD), which is used as an enzyme replacement therapy for Gaucher disease, was named one of the Five Most Promising Drugs Entering Phase III Trials in the third quarter issue of The Ones to Watch report published by Thomson Scientific, part of The Thomson Corporation.
A copy of the press release dated December 3, 2007, is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits 


 
        
                        
99.1
 
        
                        
Press release dated December 3, 2007, titled “Protalix BioTherapeutics’ prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific.”
  

 
 
2
 




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 


 
        
                        
 
 
        
                        
 
 
        
                        
 
 
        
                        
PROTALIX BIOTHERAPEUTICS, INC.
  
 
        
                        

 Date: December 3, 2007
 
        
                        
 
 
        
                        
By: 
 
        
                        
 
 /s/ David Aviezer
  
 
        
                        
 
 
        
                        
 
 
        
                        
 
 
        
      
Name: 
 
        
                        
David Aviezer, Ph.D.
  
 
        
                        
 
 
        
                        
 
 
        
                        
 
 
        
                        
Title: 
 
        
                        
President and
 Chief Executive Officer
  

 
 
3